RTP Mobile Logo
Myeloproliferative Neoplasms Update, Issue 1, 2019
Released May 2019

Featuring interviews with Drs Ruben A Mesa and Aaron T Gerds. (Audio Program)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    OVERVIEW OF ACTIVITY
    Myeloproliferative neoplasms (MPNs) largely consist of 3 diseases all heralding from clonal disorders in which an initial molecular event results in excessive production of blood cells. Importantly, although essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF) are clinically distinguishable by laboratory and molecular parameters, they may represent a disease continuum whereby transformation from ET or PV to the more aggressive MF results in a homogenous pathologic entity with a uniformly poor prognosis. In contrast to the rather indolent natural history of untransformed ET and PV, primary MF or post-PV/ET MF is a debilitating disease. Historically no FDA-approved therapy existed, but after the FDA approval of ruxolitinib in 2011 for intermediate- and high-risk MF, including primary, post-PV and post-ET MF, this agent has rapidly been adopted in clinical practice. Patient selection and dosing of ruxolitinib remain relevant topics of discussion and debate. Not surprisingly, JAK inhibitors have been and continue to be critically evaluated for patients with both PV and ET. Most notably, in December 2014, the US FDA approved ruxolitinib as treatment for PV in patients who have experienced an inadequate response to or are intolerant of hydroxyurea. To bridge the gap between research and patient care, this issue of Myeloproliferative Neoplasms Update features one-on-one discussions with leading hematology-oncology investigators. Upon completion of this CME activity, medical oncologists and hematologists should be able to formulate an up-to-date and more complete approach to the care of patients with MPNs.

    LEARNING OBJECTIVES

    • Appraise the evidence-based therapeutic options for patients with PV, ET and MF, and develop clinical algorithms intended to enhance quality and quantity of life for these individuals.
    • Determine the role of ruxolitinib in the treatment of MF in patients with thrombocytopenia and anemia.
    • Formulate a plan for managing the side effects associated with ruxolitinib to support quality of life and continuation of treatment.
    • Recall emerging research data with the use of novel JAK inhibitors in the treatment of MF, and prepare for their potential availability in clinical practice.
    • Appreciate the biologic rationale for and available efficacy and safety data with novel agents under investigation for the treatment of MPNs.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENTS
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THESE CME ACTIVITIES
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Ruben A Mesa, MD
    Director
    Mays Cancer Center at UT Health
    San Antonio MD Anderson
    Mays Family Foundation Distinguished University Presidential Chair
    Professor of Medicine
    San Antonio, Texas

    Consulting Agreements: AOP Orphan, Novartis, Sierra Oncology; Contracted Research: AbbVie Inc, Celgene Corporation, Genentech, Incyte Corporation.

    Aaron T Gerds, MD, MS
    Assistant Professor of Medicine
    Cleveland Clinic Lerner College of Medicine
    Staff, Cleveland Clinic Taussig Cancer Institute
    Cleveland, Ohio

    Advisory Committee: Apexx Oncology, Celgene Corporation, CTI BioPharma Corp.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Celgene Corporation and Incyte Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: May 2019
    Expiration date: May 2020

Acknowledge and close

Listen to audio:
Myeloproliferative Neoplasms Update, Issue 1, 2019
Released May 2019

Featuring interviews with Drs Ruben A Mesa and Aaron T Gerds. (Audio Program)

Read print: